• Image of ORKAMBI medication

    • ORKAMBI

    • QTY 112
    • 200-125MG
    • Tablet

LUMACAFTOR; IVACAFTOR (LOO ma KAF tor; EYE va KAF tor) treats cystic fibrosis (CF). It works by improving the function of a protein in your body, which helps balance the level of salt and water in the lungs. This prevents mucus from building up in your lungs, which may improve symptoms of CF. It is not a cure for CF.

ORKAMBI Lifestyle Interactions

  • Lumacaftor 200mg, Ivacaftor 125mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Lumacaftor; ivacaftor and grapefruit juice together without approval from your prescriber. Grapefruit juice may increase the amount of Lumacaftor; ivacaftor in your blood. Contact your health care provider immediately if you experience dark yellow or brown urine, general ill feeling or flu-like symptoms, light-colored stools, loss of appetite, nausea, right upper belly pain, yellowing of the eyes or skin, or become unusually weak or tired.
    • Notes for Professionals: It may be prudent to avoid consumption of grapefruit or grapefruit juice with lumacaftor; ivacaftor if possible. If a patient has taken lumacaftor; ivacaftor uninterrupted for more than 1 week, grapefruit consumption may be acceptable. However, when initiating lumacaftor; ivacaftor, avoid consumption of grapefruit and/or its juice for a minimum of 1 week. If lumacaftor; ivacaftor therapy is interrupted for more than 1 week, consumption of grapefruit and/or its juice should be avoided until lumacaftor; ivacaftor therapy is reinstated for a minimum of 1 week. The 1-week lead-in period allows for lumacaftor's induction of CYP3A to reach steady state. Grapefruit is a potent CYP3A inhibitor, ivacaftor is a CYP3A substrate, and lumacaftor is a potent CYP3A inducer. The inhibitory effects of grapefruit and its juice may increase the systemic exposure of ivacaftor. In pharmacokinetic studies, coadministration of lumacaftor; ivacaftor with once-daily itraconazole, a strong CYP3A inhibitor, increased ivacaftor exposure by 4.3-fold. However, because lumacaftor is a strong inducer of CYP3A, the net exposure of ivacaftor at steady state is not expected to exceed that achieved with ivacaftor monotherapy (i.e., 150 mg PO every 12 hours).

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.